Omnicell, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013. Dollar amounts are in millions unless otherwise stated. The filing is unaudited.
Business context and reporting period
Omnicell provides medication and medical-supply automation systems, software, services, and medication-adherence packaging. Results include MTS, acquired in May 2012, in the Non-Acute Care segment; the prior-year reported quarter excludes MTS. The acquisition therefore makes reported year-over-year growth less comparable.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Revenue | $87.1 | $64.1 |
| Gross profit / margin | $45.4 / 52.1% | $35.7 / 55.8% |
| Operating income / margin | $4.2 / 4.8% | $3.6 / 5.8% |
| Net income | $3.4 | $2.4 |
| Diluted EPS | $0.10 | $0.07 |
| Operating cash flow | $4.1 | $7.3 |
- Product revenue was $69.2, up 42.7%; services and other revenue was $17.9, up 14.4%. MTS contributed $21.1 in segment revenue, including $19.9 of product revenue.
- Acute Care revenue was $66.0, with a 55.6% gross margin and 6.2% operating margin. Non-Acute Care revenue was $21.1, with a 41.1% gross margin and a 0.2% operating margin; the segment reported $45,000 of operating income.
- Cash and cash equivalents were $69.8 at quarter-end, versus $62.3 at December 31, 2012. Current assets were $197.1 and current liabilities $85.6, or approximately $111.5 of working capital. The filing reports no debt balance.
- Investing activities used $5.2, including $3.3 of property and equipment purchases and $1.9 of capitalized software development. Financing activities provided $8.7, primarily from employee stock-plan share issuance and related tax benefits.
- Contractual obligations included $44.3 of operating leases and $6.9 of supplier and contract-manufacturer commitments. The filing states there were no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Reported revenue rose 35.8%, primarily reflecting MTS, which was not included in Q1 2012 reported results. On a pro forma basis, revenue was $87.1 versus $83.1, an increase of approximately 4.9%.
- Gross margin declined to 52.1% from 55.8%. Product margin fell to 51.5% from 58.2%, reflecting product mix and the lower-margin Non-Acute Care contribution; services margin improved to 54.1% from 48.2%.
- Operating cash flow decreased to $4.1 from $7.3, with working-capital pressures including higher receivables and lower accrued compensation. Cash rose during the quarter, helped by employee stock-plan proceeds.
- Net income included a $0.7 discrete tax benefit from retroactive reinstatement of the 2012 federal R&D credit. The 2013 effective tax rate before discrete items was 37.4%, versus 39.6%.
Outlook, commentary, risks, and unusual items
- Management expected revenue to continue increasing in 2013, supported by existing orders and the full-year contribution from MTS. It also expected service revenue and gross profit to grow, R&D to remain relatively flat as a percentage of revenue, and SG&A to grow nominally with efficiency gains. No numerical earnings or revenue guidance was provided.
- Q1 revenue declined 3.4% sequentially from Q4 2012; gross margin fell from 54.8% to 52.1%, chiefly due to lower product margin. Management noted equipment revenue depends on customer installation timing and the company’s ability to complete installations.
- Omnicell recorded a $1.8 impairment charge for capitalized Non-Acute Care software development costs after changing the product roadmap and redesigning the project. A Non-Acute Care reorganization incurred $0.7 of severance and related costs and $0.4 of accelerated stock-option vesting expense.
- MTS generated $18.4 of revenue and a $1.0 net loss during the quarter, according to the acquisition note.
- A stolen device containing medication-dispensing logs and some patient health information led to a putative class action filed in March 2013. A court order dated May 2, 2013 required the plaintiff to show why the case should not be dismissed for lack of subject-matter jurisdiction. The company recorded no accrual, stating a loss was reasonably possible but not probable and not reasonably estimable.
- Key risks include healthcare customer capital-spending and installation delays, competition and pricing pressure, integration and performance of MTS, timely supply of consumable medication packaging, dependence on suppliers, privacy and security obligations, and potential litigation costs. Management said cash and operating cash flows were expected to fund working capital and capital expenditures for at least the next 12 months.
Important facts for investors to verify
- How much of future reported growth reflects organic demand versus MTS, and whether Non-Acute Care can improve its low operating margin.
- Whether product gross margin recovers and whether installation schedules convert backlog and orders into recognized revenue on time.
- Whether receivables and operating cash flow improve, given the Q1 working-capital outflow and reliance on employee stock-plan proceeds to support cash growth.
- The commercial and financial impact of the software redesign and impairment, the reorganization, and MTS integration.
- Developments in the patient-information incident and related litigation, including any regulatory, customer, indemnification, or financial consequences.
- The filing provides no numerical full-year guidance; investors should distinguish management’s directional expectations from formal forecasts.